Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
-
Published:2018-07
Issue:1
Volume:69
Page:60-69
-
ISSN:0168-8278
-
Container-title:Journal of Hepatology
-
language:en
-
Short-container-title:Journal of Hepatology
Author:
Lyu NingORCID,
Kong Yanan,
Mu Luwen,
Lin Youen,
Li Jibin,
Liu Yaru,
Zhang Zhenfeng,
Zheng Lie,
Deng Haijing,
Li Shaolong,
Xie Qiankun,
Guo Rongping,
Shi Ming,
Xu Li,
Cai Xiuyu,
Wu Peihong,
Zhao Ming
Reference43 articles.
1. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015;Akinyemiju;JAMA Oncol,2017
2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009
3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
4. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma;Bruix;Gastroenterology,2016
5. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma;Chen;Cancer Lett,2015
Cited by
189 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献